IP Library Granted Patent US 8,486,060
Granted Patent B2
US 8,486,060 · App. 11/532,889 · Granted Jul 16, 2013

Power ramping during RF ablation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,486,060
App. No.
11/532,889
Granted
Jul 16, 2013
Kind
B2
Abstract

A method for tissue ablation is described. An RF applicator including an electrode carrier with one or more bipolar electrodes thereon is positioned at a target tissue site for tissue ablation. A current at an initial current level is passed through the one or more bipolar electrodes to the target tissue site to apply an initial power density to destroy tissue for an initial time period. A vacuum source in fluid communication with the RF applicator is employed to remove moisture generated during ablation away from the target tissue site. After the initial time period, the power density is ramped up by increasing the current passed through the one or more bipolar electrodes to the target tissue site for a second time period.

Claims (25)

1. A method for tissue ablation comprising:

positioning a radiofrequency (RF) applicator comprising an electrode carrier with one or more bipolar electrodes thereon at a target tissue site within a body cavity for ablating the interior lining of the body cavity;

passing a current at an initial current level through the one or more bipolar electrodes to the target tissue site to apply an initial power density to destroy tissue, wherein power is applied at said initial current level for an initial time period;

employing a vacuum source in fluid communication with the RF applicator to remove fluid generated during ablation away from the target tissue site, wherein excess fluid not removed by the vacuum source builds up at the target tissue site; and

after the initial time period, ramping up the power density by increasing the current passed through the one or more bipolar electrodes to the target tissue site for a second time period, wherein the excess fluid build-up is vaporized during said second time period.

2. The method of claim 1 , wherein ramping up the power density comprises steadily increasing the current over the second time period.

3. The method of claim 1 , wherein ramping up the power density comprises suddenly increasing the current from the initial current level to a second current level and applying the second current level for the second time period.

4. The method of claim 1 , further comprising:

monitoring an impedance level at an interface between the target tissue site and the RF applicator; wherein the impedance is at an initial impedance level at the outset of passing the current and the initial time period ends when a threshold decrease in the impedance level below the initial impedance level is detected.

5. The method of claim 4 , where the second time period begins when the threshold decrease in impedance level is detected and ends when the impedance level is detected as having returned to substantially the initial impedance level, the method further comprising:

after the second time period ends, decreasing the power density to the initial power density.

6. The method of claim 5 , further comprising: after decreasing the power density to the initial power density, steadily increasing the power density over a third time period.

7. The method of claim 4 , wherein the target tissue site is a tubal ostium in a female uterine cavity; the initial power density is approximately 5 watts per square centimeter; the threshold decrease in the impedance level detected is a decrease of approximately 25%; and the power density is increased during the second time period at a rate of approximately 1 watt per square centimeter per second.

8. The method of claim 4 , where: the target tissue site is a tubal ostium in a female uterine cavity; the initial power density is approximately 5 watts per square centimeter; the threshold decrease in the impedance level detected is a decrease of approximately 33%; and the power density is increased during the second time period at a rate of approximately 2.5 watts per square centimeter per second.

9. The method of claim 4 , where: the target tissue site is a tubal ostium in a female uterine cavity; the initial power density is approximately 5 watts per square centimeter; the threshold decrease in the impedance level detected is a decrease of approximately 50%; and the power density is increased during the second time period to a level of approximately 10 to 15 watts per square centimeter.

10. The method of claim 1 , where the initial time period is determined empirically as a time period after which an initial depth of tissue destruction has been achieved.

11. The method of claim 10 , where: the target tissue site is a tubal ostium in a female uterine cavity; the initial power density is approximately 5 watts per square centimeter; the initial time period is between approximately 45 and 60 seconds; the power density is increased during the second time period at a rate of approximately 1 watt per square centimeter per second; and the second time period is between approximately 5 and 10 seconds.

12. The method of claim 10 , where: the target tissue site is a tubal ostium in a female uterine cavity; the initial power density is approximately 5 watts per square centimeter; the initial time period is between approximately 10 and 60 seconds; the power density is increased during the second time period at a rate of approximately 0.5 to 2.5 watts per square centimeter per second; and the second time period is between approximately 5 and 10 seconds.

13. A method for tissue ablation comprising:

positioning a radiofrequency (RF) applicator comprising an electrode carrier with one or more bipolar electrodes thereon at a target tissue site for tissue ablation;

passing a current at an initial current level through the one or more bipolar electrodes to the target tissue site to apply an initial power density to destroy tissue, wherein power is applied at said initial current level for an initial time period;

employing a vacuum source in fluid communication with the RF applicator to remove moisture generated during ablation away from the target tissue site, wherein excess fluid not removed by the vacuum source builds up at the target tissue site;

monitoring an impedance level at an interface between the target tissue site and the RF applicator;

detecting an impedance level decrease from an initial level detected at the outset of passing the current by a threshold amount;

after the impedance level decrease has been detected, ramping up the power density by increasing the current passed through the one or more bipolar electrodes to the target tissue site for a second time period, wherein the excess fluid build-up is vaporized during said second time period.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
TERMINATION OF PATENT SECURITY AGREEMENTS AND RELEASE OF SECURITY INTERESTS Recorded Aug 26, 2010
From: GOLDMAN SACHS CREDIT PARTNERS, L.P., AS COLLATERAL AGENT
To: HOLOGIC, INC.; R2 TECHNOLOGY, INC.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; DIRECT RADIOGRAPHY CORP.; CYTYC SURGICAL PRODUCTS II LIMITED PARTNERSHIP; CYTYC SURGICAL PRODUCTS LIMITED PARTNERSHIP; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS III, INC.; CYTYC PRENATAL PRODUCTS CORP.; THIRD WAVE TECHNOLOGIES, INC.
Reel/Frame 024892/0001 →
PATENT SECURITY AGREEMENT Recorded Jul 29, 2008
From: CYTYC SURGICAL PRODUCTS
To: GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT
Reel/Frame 021311/0118 →
PATENT SECURITY AGREEMENT Recorded Oct 26, 2007
From: CYTYC SURGICAL PRODUCTS
To: GOLDMAN SACHS CREDIT PARTNERS L.P.
Reel/Frame 020018/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2007
From: KOTMEL, ROBERT; SAMPSON, RUSSEL M.; TAYLOR, SCOTT DENNIS
To: CYTYC CORPORATION
Reel/Frame 019457/0225 →